Description

Green Cross Holdings Corporation operates as a leading biotechnology firm. Its extensive product range includes plasma-derived therapies, a variety of prescription and over-the-counter medications, and specialized drugs for conditions such as Hunter syndrome. The company is also a significant producer of vaccines, protecting against diseases like hemorrhagic fever, varicella (chickenpox), hepatitis B, and influenza. Beyond its current offerings, Green Cross Holdings is deeply invested in research and development, focusing on breakthroughs in oncology, immunology, and cell-based therapies. It also provides recombinant protein treatments for individuals with hemophilia. To drive innovation, the company actively forms strategic partnerships and collaborations with other biotech enterprises and academic institutions to advance new drug and technology development. Founded in 1967, Green Cross Holdings is headquartered in Yongin, South Korea.